Financial Highlights -consolidated-

Composition Ratio of Sales

March 31, 2024

10.2%

Microbiological Reagents

Reagents that are effective for diagnosis and treatment of microorganism infection, such as mediums, antimicrobial susceptibily tests and rapid test reagents.

11.0%

Urinalysis Test Strips

Urine analysis test strips for testing various items such as occult blood, protein and glucose.

32.2%

Fecal Immunochemical Tests Reagents

Our major products are reagents and sampling bottles for fecal immunochemical tests for screening of colon cancer.

23.4%

Immunological and Serological Reagents

Reagents to diagnose and measure infectious disease, rheumatism, inflammation, atrophic gastritis, and prostate specific antigens.

1.4%

Clinical Chemistry Test Reagents

Reagents for clinical chemistry tests that assist to measure and analyze biological components in blood serum and urine, with a focus on the test items that are related to lifestyle related diseases.

4.3%

Equipment/ Culture Mediums Related to Food and Environment

Reagents for microbiological tests on food to detect food poisoning bacteria as well as reagents for environmental microbiological tests and equipment and devices to measure contamination of work environments.

4.7%

Molecular genetics (LAMP)

Reagents using the LAMP method, gene amplification technology.

12.7%

Medical Devices

Various types of automated analyzers. They contract manufacturing specialized equipment that uses their in-house reagent.

（millions of yen）

　 FY2020
(April 1, 2020 to March 31, 2021)		 FY2021
(April 1, 2021 to March 31, 2022)		 FY2022
(April 1, 2022 to March 31, 2023)		 FY2023
(April 1, 2023 to March 31, 2024)		 FY2024
(April 1, 2024 to March 31, 2025)		 FY2025
(April 1, 2025 to March 31, 2026)
Sales 38,667 42,996 43,271 40,052 40,539 41,899
Net sales to overseas 6,895 8,868 8,797 10,115 10,710 11,457
Gross profit 18,529 20,564 20,506 16,723 16,512 16,175
Operating income 6,612 8,387 7,457 3,377 2,999 2,919
Operating income margin (%) 17.1 19.5 17.2 8.4 7.4 7.0
Ordinary income 6,808 8,508 7,568 3,568 3,198 2,844
Net income 5,044 6,218 5,736 2,634 2,228 3,708
Net income per share (Yen)  136.65 168.28 155.17 71.69 64.82 112.52
Total assets 55,685 62,512 66,275 61,651 62.372 62,657
Net assets 41,672 45,803 49,535 45,971 43.598 44,034
Equity ratio (%) 74.3 72.8 74.2 74.0 69.3 70.1
Net assets per share (Yen)  1,120.36 1,230.55 1,327.47 1,318.38 1,294.08 1,333.07
ROE (%) 12.9 14.3 12.1 5.6 5.0 8.5
ROA (%) 9.5 10.5 8.9 4.1 5.2 4.5
Operating Cash Flow 5,451 7,769 7,575 3,806 6,033 4,045
Investing Cash Flow -2,193 -5,044 -316 -2,216 -4,499 -3,423
Financing Cash Flow -1,275 1,200 -2,095 -6,694 -4,857 -322
R&D expenses 3,086 3,408 4,065 3,939 4,386 3,676
Capital investment 2,876 4,347 3,792 1,812 7,699 3,817
Depreciation 1,711 2,058 2,125 2,326 2,533 2,528

 

Management
policy

IR Library

Stock
Information

Financial Highlights
-consolidated-